Indications -- Lupus/Nephritis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (17)	4/24/2001 3:09:05 PM
From: scaram(o)uche	Read Replies (2) of 95

I performed DD for a major underwriter, 5/95. I recommended against a banking relationship. My confidentiality agreement is dated 5/3/95, and all obligations were limited to a period of five years. The proposed mechanism was induction of tolerance. Many, many observations have flowed by. There's been tons of spin and Abbott was, IMO, nuts. In 1995, I said "passive absorption, not tolerance". Now we're looking only at a subset of patients who have antibodies that react with the (IMO) adsorbent and at therapy with no "off" period. Hilarious. This is what happened to some old-time biotechs..... single-product companies, desperate to make it work...... quote.yahoo.com Again!! I urge everyone to look at old-time biotechs with a critical eye. Have they lost momentum and/or objectivity? Have they lost key personnel? Do they have access to critical expertise and "no people" (as opposed to "yes men") on a daily basis? I'm not saying that this subset of patients won't benefit from therapy. Wilder..... given your passion for the sector, you might profit from slowly digging through all of the posts to all three of the T/FIF threads. Just a thought.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next